This content is intended for healthcare professionals in Europe only.

Please confirm that you are a healthcare professional in Europe.

Decline

This activity has been sponsored by Advanced Accelerator Applications International SA. Advanced Accelerator Applications International SA provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY / touchENDOCRINOLOGY.

touchFEATURE

Disease burden and unmet needs of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET)

Access to this content is not permitted for healthcare professionals based in the US.

Back to Learning Zone
Gastrointestinal Oncology, Pancreatic Cancer View Time: 8 mins

touchFEATURE Disease burden and unmet needs of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET)

Watch to learn more about the impact of GEP-NET on patients, and the need for earlier diagnosis.

 
Videos
Patient experience and unmet needs in the management of GEP-NET

Dr Rocío García-Carbonero, Head of GI Neuroendocrine Tumours Unit at Hospital Universitario 12 de Octubre, Madrid, Spain, discusses the results of patient surveys, which reveal the substantial impact of GEP-NET on patients’ personal and working lives.1,2 These surveys highlight unmet needs for earlier diagnosis and better access to NET specialist centres.1,2

1/2 Next Chapter
 
Importance of early diagnosis for patients with GEP-NET

Dr Christos Toumpanakis, Consultant in Gastroenterology & Neuroendocrine Tumours at the Royal Free Hospital, London, UK, discusses the benefits of early diagnosis of GEP-NET3,4 and provides recommendations for improving symptom awareness and early detection.

2/2 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

Many patients with neuroendocrine tumours (NET), including gastroenteropancreatic NET (GEP-NET), experience delayed diagnosis,1-3 which is associated with stress and burnout – psychological symptoms that can compromise quality of life.3 More advanced (e.g. unresectable or metastatic) disease at diagnosis may result in reduced therapeutic options and worse survival outcomes.4,5

Learning Objectives

After watching this activity, participants should be better able to:

  • Recognise the potential impact of GEP-NET on patients’ personal and working lives1,2
  • Recall key unmet needs for patients with GEP-NET1,2
  • Understand the importance of early diagnosis for patients with GEP-NET2,3
References
References
  1. Singh S, Granberg D, Wolin E, et al. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol. 2016;3(1):43-53.
  2. Wolin EM, Leyden J, Goldstein G, et al. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States. Pancreas. 2017;46(5):639-647.
  3. Keizer AC, Korse TCM, Meijer WG, Tesselaan MET. The effect of delay in diagnosis in patients with neuroendocrine tumors. Int J Endocrine Oncol. 2016;3:33-39.
  4. Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel). 2022;14(8):2028.
  5. Kos-Kudła B, Ćwikła J, Ruchała M, et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemp Oncol (Pozn). 2017;21(2):115-122.
Downloads

View and download resources from this activity to support your learning and share with colleagues

Feedback Close
Feedback

Please provide feedback for this touchFEATURE on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72